| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514099000 | Oxygen containing hetero ring | 72 |
| 20080269173 | Composition for Stimulating Growth of Dermal Papilla Cells and Promoting Hair Follicle Growth Comprising Vitamin C Derivatives - Disclosed is a composition for stimulating growth of dermal papilla cells and promoting hair follicle growth comprising vitamin C derivatives. | 10-30-2008 |
| 20090075942 | DEUTERIUM-ENRICHED FOSAMPRENAVIR - The present application describes deuterium-enriched fosamprenavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
| 20090221530 | Relaxase Modulators and Methods of Using Same - Methods of treating a microbial infection in a subject by administering to the subject an effective amount of a compound that modulates an enzymatic activity of a relaxase polypeptide is provided. Methods of inhibiting bacterial conjugation by modulating activity of a relaxase polypeptide in a bacterium are also provided. Novel compounds that modulate relaxase enzymes and assays for measuring kinetics of relaxase enzymes and selecting for modulators of relaxase enzyme activity are further provided. | 09-03-2009 |
| 20100063005 | Methods for Treating Cystic Fibrosis or Pneumonia with Bacterial Infection via Pulmonary Administration of Fosfomycin - The present invention provides methods for treating a bacterial infection and/or bacterial airway colonization in a subject by administering via pulmonary administration an effective amount of fosfomycin as the only active pharmaceutical ingredient. Methods of the present invention are useful in treating bacterial pneumonia infection of any type and/or airway colonization, cystic fibrosis with bacterial infection and/or bacterial lung and/or airway colonization. | 03-11-2010 |
| 20100105638 | COSMETIC COMPOSITIONS - The present invention relates to the use of ascorbyl phosphate and niacinamide to suppress the crystallization of biotin in cosmetic or dermatological compositions. Furthermore, the invention relates to cosmetic or dermatological compositions comprising ascorbyl phosphate, niacinamide, biotin and a cosmetically acceptable carrier. | 04-29-2010 |
| 20100152139 | EMULSIFIED SKIN EXTERNAL PREPARATION AND METHOD FOR STABILIZING THE SKIN EXTERNAL PREPARATION - An emulsified skin external preparation containing a salt of a higher fatty acid ester of ascorbic acid-2-phosphate is provided, and the decomposition and consequent decrease of the salt are prevented and thereby the stability of the preparation is enhanced. A method for stabilizing the skin external preparation containing a salt of a higher fatty acid ester of ascorbic acid-2-phosphate is provided. The emulsified skin external preparation includes 0.03 to 25% by mass of a salt of a higher fatty acid ester of ascorbic acid-2-phosphate (A), and 0.05 to 25% by mass of a glycerin mono fatty acid ester (B), the higher fatty acid ester of ascorbic acid-2-phosphate being represented by Formula (1): . . . (1) wherein R is a higher fatty acid residue. | 06-17-2010 |
| 20100204184 | Phosphonates useful as modulators of T-gamma-9-delta-2 activity - The invention concerns novel phosphonate derivatives, preparation method, use thereof as ligands modulating T γ9δ2 lymphocyte activity and pharmaceutical compositions comprising them. | 08-12-2010 |
| 20100249072 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS - Described herein are neutral prodrugs of phosphorus-containing inhibitors of farnesyl transferase that include one or more phosphate fragments or analogs of phosphate fragments. Analogs of phosphate fragments include various linkers other than oxygen connecting the phosphate fragment to the remaining portion of the drug, such as but not limited to linkers forming phosphoramidates, phosphonates, difluorophosphonates, phosphordiamidates, and the like. | 09-30-2010 |
| 20120065171 | FOSTRIECIN DERIVATIVES AND THE PHARMACEUTICAL USES THEREOF - Novel Fostriecin (or FST) derivatives represented by formula (I), the pharmaceutical compositions and preparation methods thereof. The pharmaceutical uses of these compounds, especially the use for the preparation of pharmaceutical compositions for treating tumor, inhibiting cell over growth, or lowering myocardial infarction and the injury to cells. | 03-15-2012 |
| 20120135965 | AMORPHOUS FOSAMPRENAVIR CALCIUM - The present invention relates to amorphous Fosamprenavir calcium and processes for its preparation, a pharmaceutical composition comprising it and a method for treating a HIV infection therewith. | 05-31-2012 |
| 20120208787 | CRYSTALLINE FORM OF FOSAMPRENAVIR CALCIUM - The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention further relates to a pharmaceutical composition comprising crystalline Form II of fosamprenavir calcium. The present invention relates further to a method of treating a HIV infection using crystalline Form II of fosamprenariv calium. | 08-16-2012 |
| 20130225532 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES - Methods and compositions for detection of drug resistant pathogens and treatment against infections thereof are provided. Methods for detection of oseltamivir-resistant influenza viruses by competitive binding assays utilizing non-oseltamivir influenza virus neuraminidase inhibitors and oseltamivir carboxylate are provided. Influenza virus neuraminidase inhibitors coupled to sensors and useful for employment in the methods of the invention are disclosed. Novel phosphonate compounds active as neuraminidase inhibitors against wild-type and oseltamivir-resistant influenza strains of H1N1, H5N1 and H3N2 viruses are disclosed. An enantioselective synthetic route to preparation of these phosphonate compounds via sialic acid is provided. | 08-29-2013 |
| 20130274229 | ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY - Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents. | 10-17-2013 |
| 20130316983 | DRUG SCREENING METHOD, COMPOSITIONS AND METHODS OF TREATING GLAUCOMA - Methods are disclosed for treating glaucoma by treating a novel target. Methods for treating glaucoma by restoring the filtration capabilities of the endothelial lining of Schlemm's canal are provided. A method for identifying compounds capable of restoring the filtration capability of the juxtacanalicular meshwork is also provided. | 11-28-2013 |
| 20140080790 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE - Compounds represented by formula (I): | 03-20-2014 |
| 20140378417 | W/O/W EMULSION HAVING TEMPORAL STABILITY AND METHOD FOR PRODUCING THE SAME - An object of the present invention is to provide a W/O/W emulsion having temporal stability, which comprises a water soluble active component in an inner aqueous phase, and a method for producing the same. | 12-25-2014 |
| 20150011511 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE - Compounds represented by formula (I): | 01-08-2015 |
| 20150025040 | NOVEL POLYMORPHS OF FOSAMPRENAVIR CALCIUM - Crystalline Forms of fosamprenavir calcium are disclosed, processes for its preparation and pharmaceutical compositions therefrom. The process for the preparation of fosamprenavir calcium crystalline Form H1, comprises: a) suspending fosamprenavir calcium in a nitrile solvent; b) heating the suspension obtained in step (a) at reflux; c) optionally adding a solvent to the reaction mass obtained in step (b); d) cooling the reaction mass at below 35 degrees Centigrade; and e) isolating fosamprenavir calcium crystalline Form H1. Another process for the preparation of substantially pure amorphous fosamprenavir calcium, which comprises: a) dissolving fosamprenavir calcium in an ester solvent; b) a portion of solvent from the solution obtained in step (a) until at least separation of fosamprenavir calcium as solid occurs; and c) isolating substantially pure amorphous fosamprenavir calcium. The pharmaceutical composition may comprse substantially pure amorphous fosamprenavir calcium and pharmaceutically acceptable excipients. | 01-22-2015 |
| 20150031650 | ASCORBIC ACID DERIVATIVE COMPOSITION AND PRODUCTION METHOD OF THE SAME, ASCORBIC ACID DERIVATIVE SOLUTION, AND SKIN EXTERNAL PREPARATION - An ascorbic acid derivative composition of a first aspect according to the present invention consists of a salt of a compound (1) represented by a general formula (1) shown below; and a salt of a compound (2) represented by a general formula (2) shown below, wherein a ratio of the salt of the compound (2) with respect to a total amount of the salt of the compound (1) and the salt of the compound (2) is from 0.1 to 10% by mass, | 01-29-2015 |
| 20150148315 | Method for Improving Drug Treatments in Mammals - An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants. | 05-28-2015 |
| 514100000 | Polycyclo ring system having the hetero ring as one of the cyclos | 50 |
| 20080221070 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH - Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R | 09-11-2008 |
| 20080275005 | MITOCHONDRIALLY TARGETED ANTIOXIDANTS - The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph | 11-06-2008 |
| 20090005348 | Compounds Having Cytokine Modulating Properties - A method of modulating one or more immuno-regulatory cytokines, such as pro-inflammatory and/or anti-inflammatory cytokines, comprising administering to a subject a therapeutically effective amount of one or more phosphate derivatives of one or more hydroxy chromans, or complexes thereof. | 01-01-2009 |
| 20090054376 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES - The present invention relates to novel benzofuran compounds, to pharmaceutical compositions that include such compounds, and to methods of use thereof. Certain compounds of the invention share some pharmacological properties with cannabinoids and have a common wide range of beneficial therapeutic indications. In particular, compounds of the invention are useful as analgesic, neuroprotective, immunomodulatory and anti-inflammatory agents. | 02-26-2009 |
| 20090069273 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS - The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents. | 03-12-2009 |
| 20090082313 | Multikinase Inhibitors for Use in the Treatment of Cancer - The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): | 03-26-2009 |
| 20090170814 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES - 7,8-Bicyclic-chroman derivatives of Formula I: | 07-02-2009 |
| 20090186856 | MICRONUTRIENT PHOSPHATES AS DIETARY AND HEALTH SUPPLEMENTS - There is provided a dietary or health supplement comprising an effective amount of a micronutrient selected from the group consisting of phosphate derivatives of tocopherol, ubiquinol, ascorbic acid, tocotrienol, retinol and mixtures thereof delivered with an acceptable carrier. | 07-23-2009 |
| 20090203649 | DERMATOLOGICAL ANTI-WRINKLE AGENT - A dermatological anti-wrinkle agent and an anti-wrinkle cosmetic are stable and satisfactorily effective against wrinkles. | 08-13-2009 |
| 20090239827 | COMPOUNDS HAVING LIPID LOWERING PROPERTIES - There is provided a therapy for lowering the blood levels of a lipid selected from the group comprising LDL cholesterol, triglycerides, overall cholesterol and mixtures thereof, the therapy comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents. | 09-24-2009 |
| 20090291923 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES - The invention provides novel trioxane dimers having formulae III, IV or V: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer and/or malaria using these compounds and compositions. | 11-26-2009 |
| 20090325906 | Methods and compositions for therapeutic treatment - Methods and compositions are described for the modulation of hyperglycemia and/or one or more symptoms of hyperglycemia. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of calcineurin inhibitors out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity to increase the efflux of calcineurin inhibitor from physiological compartments. | 12-31-2009 |
| 20100004208 | SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS - The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors. | 01-07-2010 |
| 20100004209 | [(4-Oxo-4H-chromen-3-yl)hydroxymethyl]- or [(4-oxo-4H-chromen-3-yl)methyl]phosphonic acid derivatives - The present invention relates to compounds of the formula (I), where R | 01-07-2010 |
| 20100016261 | CHEMICAL COMPOUNDS - A compound of formula (I) is described; wherein the substituents are as defined in the text and wherein the compound is intended for use in the production of a vascular damaging effect in a warm-blooded animal. | 01-21-2010 |
| 20100048512 | RADIATION PROTECTION DRUG CONTAINING TOCOPHEROL OR TOCOTRIENOL COMPOUND ESTER DERIVATIVE AS ACTIVE INGREDIENT - Administration of either a tocopherol represented by the general formula (1) or a tocotrienol compound ester derivative before or after exposure to radiation is effective in preventing or treating health disorders caused by the radiation exposure. | 02-25-2010 |
| 20100130448 | 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULATN OF MUCUS SECRETION, METHOD FOR THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides a 3′,4′,5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient. | 05-27-2010 |
| 20100267673 | PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS - Tocopheryl succinate derivatives according to formula I: | 10-21-2010 |
| 20100298272 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME - A new anticancer compounds of formula (1) Drugs and pharmaceutical compositions to be used in human or veterinary medicine, which include at least one compound of formula (1). A method of treating and/or preventing cancer in a human or an animal using the compound of formula (1) | 11-25-2010 |
| 20100305070 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer. | 12-02-2010 |
| 20110003774 | COMPOUNDS HAVING ANTI-PROLIFERATIVE PROPERTIES - There is provided a method of inhibiting the occurrence of one of more of the following conditions:—the proliferation of monocytes/macrophages; or—the proliferation of smooth muscle cells; or—the expression of CD36 receptors; or—the uptake of oxidized LDL, the method comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents. | 01-06-2011 |
| 20110028437 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS - The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents. | 02-03-2011 |
| 20110105437 | Mitochondrially Delivered Anti-Cancer Compounds - This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant vitamin E analogue, such as α-tocopheryl succinate, α-tocopheryl maleate, α-tocopheryl maleyl amide, or 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (α-tocopheryloxyacetic acid). | 05-05-2011 |
| 20110124603 | Trioxane Dimer Sulfur Compounds - The disclosure provides novel trioxane sulfur dimers having Formula I: | 05-26-2011 |
| 20110130367 | Combination Therapy for Treating Proliferative Diseases - The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer. | 06-02-2011 |
| 20110144062 | DERMATOLOGICAL ANTI-WRINKLE AGENT - A dermatological anti-wrinkle agent and an anti-wrinkle cosmetic are stable and satisfactorily effective against wrinkles. The dermatological anti-wrinkle agent includes a tocopherol phosphate represented by the following formula (1): | 06-16-2011 |
| 20110281824 | BENZOFURAN DERIVED HIV PROTEASE INHIBITORS - Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided. | 11-17-2011 |
| 20120214770 | SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS - The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors. | 08-23-2012 |
| 20120232038 | CRYSTALLINE FORMS OF (3R, 3AS, 6AR) - HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R) - (1-{4-[ (DIETHOXYPHOSPHORYL) METHOXY] PHENY1}-3-HYDROXY-4- [4-METHOXY-N- (2-METHYLPROPYL) BENZENESUL - FONAMIDO] BUTAN-2-YL) CARBAMATE - The present inventions provides crystalline forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-(1-{4-[(diethoxyphosphoryl)methoxy]phenyl}-3-hydroxy-4-[4-methoxy-N-(2-methylpropyl)benzenesulfonamido]butan-2-yl)carbamate, methods of preparing the crystalline forms, pharmaceutical compositions containing the crystalline forms, and therapeutic uses thereof. | 09-13-2012 |
| 20120238529 | TRIPTOLIDE PRODRUGS - The invention provides compounds of formula (I): or a salt thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using the compounds of formula I. | 09-20-2012 |
| 20120252763 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS - The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds. | 10-04-2012 |
| 20120258935 | PROCESS FOR PREPARATION OF HIV PROTEASE INHBITORS - A process for the synthesis of bisfuran intermediates useful for preparing antiviral HIV protease inhibitor compounds is hereby disclosed | 10-11-2012 |
| 20120264718 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 10-18-2012 |
| 20120289484 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME - Described herein are Δ | 11-15-2012 |
| 20130053351 | SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS - The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors. | 02-28-2013 |
| 20130143844 | ECTOPARASITICIDE-CONTAINING PREPARATION FOR SPONTANEOUS EMULSION FORMATION - An emulsion concentrate for spontaneous emulsion preparation is described, comprising at least one ectoparasiticidal active ingredient. Moreover, a process for the preparation of a corresponding emulsion concentrate, and also its use for producing emulsions are described. An emulsion which is obtained starting from the emulsion concentrate, and also its use, are also described. | 06-06-2013 |
| 20130172295 | PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS - A process for the synthesis of bisfuran intermediates useful for preparing antiviral HIV protease inhibitor compounds is hereby disclosed | 07-04-2013 |
| 20130303489 | MULTIKINASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER - The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): | 11-14-2013 |
| 20130345176 | NOVEL ESTERS OF 4, 9-DIHYDROXY-NAPHTHO [2, 3-b] FURANS FOR DISEASE THERAPIES - The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9-dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases. | 12-26-2013 |
| 20140107077 | TRIPTOLIDE PRODRUGS - The invention provides compounds of formula I: | 04-17-2014 |
| 20140288027 | Derivative of Butylphthalide and Preparation Method and Use Thereof - (−)-(S)-3-(3′-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels. | 09-25-2014 |
| 20150011512 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer. | 01-08-2015 |
| 20150307533 | SPIROCYCLIC SULFONES AS GAMMA SECRETASE INHIBITORS - Disclosed herein are compounds of Formula (I), wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease. | 10-29-2015 |
| 20150322034 | PRO-DRUG COMPOUNDS - A compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein Z | 11-12-2015 |
| 20150361088 | TWO-CARBON LINKED ARTEMISININ-DERIVED TRIOXANE DIMERS - Two-carbon linked artemisinin-derived trioxane dimers and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer. | 12-17-2015 |
| 20160016928 | Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals - The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them. | 01-21-2016 |
| 20160051571 | TRIPTOLIDE PRODRUGS - The invention provides compounds of formula I: | 02-25-2016 |
| 20160136190 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles - The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds. | 05-19-2016 |
| 20160175281 | IMMUNOSUPPRESSIVE COMPOUNDS AND THERAPEUTICS | 06-23-2016 |
| 20160184331 | BASE AND EXTERNAL PREPARATION FOR SKIN - An object of the present invention is to provide: a novel base that, after application to a skin surface, can rapidly form a coating film and moreover mitigates skin irritation and occurrence of odors; and an external preparation for skin. The base is used in an external preparation for skin that administers an active ingredient transdermally, and is characterized by containing at least an acrylic-based synthetic polymer and a volatile oil, wherein the base is in a liquid or ointment form prior to application to the skin surface, and the volatile oil evaporates after application of the base to form a hydrophobic coating film containing the volatile oil in the range of 0 to 60 wt % with respect to 100 parts by weight of the acrylic-based synthetic polymer. | 06-30-2016 |
| 514101000 | Two or more oxygen in the hetero ring | 2 |
| 20080249067 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells - The present invention describes organophosphorus compounds of general formula (I) | 10-09-2008 |
| 20140045797 | Bisphosphonate-Prostatic Acid Phosphatase Inhibitor Conjugates To Treat Prostate Cancer Bone Metastasis - The present invention concerns conjugate compounds comprising a bisphosphonate covalently bonded to a prostatic acid phosphatase inhibitor and compositions comprising such conjugates. Methods for treating and inhibiting prostate cancer bone metastases, and determining whether a conjugate is useful for such treatment are also provided. In some instances, the bisphosphonate is alendronate, and it is covalently bonded to either tartaric acid or glyceric acid. | 02-13-2014 |
